Multi−scale evaluation of spider toxins as potential anti−nociceptive agents: example of Cyriotoxin−1a
Résumé
Aim
Our expertise is the identification and structural and functional characterization of original natural toxins targeting receptors and ion channels, and which may have applications in human health. In this context, and in collaboration with the Institut du Thorax, Smartox Biotechnology and Sanofi R & D, we are interested in the multi-scale evaluation (from the cell in vitro to the organism in vivo) of spider toxins as potential anti-nociceptive agents, as illustrated by the example of Cyriotoxin-1a (CyrTx-1a).
NaV1.7 channel subtype is highly expressed in dorsal root ganglia (DRG) of the sensory nervous system and plays a central role in the pain signaling process. We investigated a library prepared from original venoms of 117 different animals to identify new selective inhibitors of this target.
Methods
We used high-throughput screening of the venom library, using automated patch-clamp experiments on human voltage-gated sodium channel subtypes, and then in vitro and in vivo electrophysiological experiments to characterize the active peptides that have been purified, sequenced and chemically synthesized. Analgesic effects were evaluated in mice in vivo.
Results
We identified and further characterized CyrTx-1a, a novel peptide isolated from Cyriopagopus schioedtei spider venom. This 33 amino acids toxin belongs to the inhibitor cystine knot structural family and inhibits hNaV1.1-1.3 and 1.6-1.7 in the low nanomolar range, compared to the micromolar range for hNaV1.4-1.5 and 1.8. CyrTx-1a was 920 times more efficient at inhibiting tetrodotoxin (TTX)-sensitive than TTX-resistant sodium currents recorded from adult mouse DRG neurons in vitro, and approximately 170 times less efficient than huwentoxin-IV at altering mouse skeletal neuromuscular excitability in vivo. CyrTx-1a exhibited an analgesic effect in mice by significantly increasing reaction time in the hot-plate assay.
Main Conclusions
The pharmacological profile of CyrTx-1a paves the way for further engineering studies aimed to optimize the potential anti-nociceptive properties of this peptide.
Domaines
Pharmacologie
Fichier principal
2021-InternationalCongressEUVEN_Online-BENOIT.pdf (361.29 Ko)
Télécharger le fichier
Origine | Fichiers produits par l'(les) auteur(s) |
---|